



King Saud University
Saudi Pharmaceutical Journal
 www.ksu.edu.sa
 www.sciencedirect.com



REVIEW

Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada



Upendra C. Galgatte *, Vijay R. Jamdade, Pravin P. Aute, Pravin D. Chaudhari

PES Modern College of Pharmacy, Sector No. 21, Yamunanagar, Nigdi, Pune-411044, Maharashtra, India

Received 14 April 2013; accepted 17 May 2013
Available online 31 May 2013

KEYWORDS

Bioavailability;
Bioequivalence;
Pharmacokinetics

Abstract The present study was aimed to study the requirements of bioequivalence for the registration of pharmaceutical products in the USA, Europe and Canada. Before going into bioequivalence studies it is essential for the pharmaceutical industry to study the guidelines of bioequivalence for the respective country where the industry wants to market its products and thus enter into generic market. This study reviews the requirements of bioequivalence with study parameters such as study design, fasting or fed state studies, volunteers recruitment, study dose, sampling points, analytical method validation parameters, moieties to be measured in plasma, pharmacokinetic parameters, criteria for bioequivalence, GCP requirements etc, which are needed for the pharmaceutical industry to carry out bioequivalence studies and to file ANDA. Test products and reference products are needed for this study. Test products are usually manufactured by a sponsor and reference products are provided by the government laboratories of the respective countries. Sampling points also vary with respect to the regulatory guidelines of these countries. All these countries follow ICH GCP guidelines. The criterion of bioequivalence for these countries is 90% CI 80–125% for C_{max} , AUC_t , $AUC_{0-\infty}$.

© 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.


Contents

1. Introduction	392
2. Bioequivalence study requirements for the registration of the pharmaceutical product in the USA	393

* Corresponding author. Tel.: +91 (20) 27661315/14, mobile: +91 9890755938; fax: +91 (20) 27661314.

E-mail address: ucgpharm@rediffmail.com (U.C. Galgatte).

Peer review under responsibility of King Saud University.



2.1.	Experimental design	393
2.2.	Sample size and dropouts	393
2.3.	Food-effect bioavailability and fed bioequivalence studies	393
2.4.	Potential mechanisms of food effects on bioavailability	393
2.5.	Study considerations	393
2.6.	Subject selection	393
2.7.	Dosage strength	393
2.8.	Test meal	394
2.9.	Administration	394
2.9.1.	Fasted treatments	394
2.9.2.	Fed treatments	394
2.10.	Sample collection	394
2.11.	Moieties to be measured	394
2.12.	Collection of biological matrix and sampling schedule	394
3.	Bioequivalence study requirements for registration of pharmaceutical product in Europe	395
3.1.	Design	395
3.2.	Subjects	395
3.2.1.	Number of subjects	395
3.2.2.	Selection of subjects	395
3.3.	Study conduct	395
3.3.1.	Standardization	395
3.3.2.	Sampling times	395
3.3.3.	Fasting or fed conditions	395
3.4.	Reference and test product	395
4.	Bioequivalence study requirements for registration of pharmaceutical product in Canada	396
4.1.	Choice of subjects	396
4.2.	Considerations in subject characteristics	396
4.2.1.	Age	396
4.2.2.	Height/weight ratio	396
4.2.3.	Health	396
4.3.	Number of subjects	396
4.4.	Drop-outs and withdrawal of subjects from a study	396
4.5.	Study design and environment	396
4.6.	Standardization	396
4.7.	Blinding	397
4.8.	Administration of food and fluid	397
4.9.	Sampling times	397
4.10.	Sampling of blood or urine	397
4.11.	Test and reference drug products	397
4.11.1.	Selection of reference product	397
5.	Format and content of the report on bioequivalence studies to be submitted	397
5.1.	United States	401
5.2.	Europe	401
5.3.	Canada	401
6.	Conclusion	401
References	401

1. Introduction

The concepts of bioavailability (BA) and bioequivalence (BE) have gained considerable importance during the last three decades because of their application to new brand-name drugs, as well as to generic drugs. During this period, regulatory authorities also started developing and formulating the regulatory requirements for the approval of generic drug products. Consequently, tremendous advances have been made in the application of assessment approaches to these scientific concepts. BA and BE have become the cornerstones for the approval of brand-name and generic drugs globally and have been uti-

lized for brand-name drugs to reduce the cost of development. It is encouraging to know that there are continuing efforts by regulatory authorities and the scientific community, both nationally and internationally, to understand and develop more efficient and scientifically valid approaches to the assessment of BE of various dosage forms including some of the tough complex special dosage forms. Because of the importance of generic drugs in healthcare, it is imperative that the pharmaceutical quality and *in vivo* performance of generic drugs be reliably assessed (Midha and McKay, 2009). Because generic drugs would be interchanged with innovator products in the market place, it must be demonstrated that the safety

Download English Version:

<https://daneshyari.com/en/article/2509300>

Download Persian Version:

<https://daneshyari.com/article/2509300>

[Daneshyari.com](https://daneshyari.com)